Phase IIIb trial of fezolinetant shows positive topline results for treatment of vasomotor symptoms – due to menopause – Astellas

Astellas Pharma Inc. announced positive topline results from the Phase IIIb DAYLIGHT clinical trial for fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate to severe vasomotor symptoms (VMS) due to menopause . VMS, characterized by hot flashes and/or night sweats, are common symptoms of menopause. The study, comprised of more than 450 women considered unsuitable […]